000650 仁和药业
已收盘 04-26 15:00:00
资讯
新帖
简况
仁和药业(000650.SZ)发布2023年度业绩,净利润5.67亿元,下降1.25%
智通财经网 · 04-25 17:28
仁和药业(000650.SZ)发布2023年度业绩,净利润5.67亿元,下降1.25%
仁和药业最新公告:拟使用合计不超30亿元进行投资理财
证券之星 · 04-25 16:51
仁和药业最新公告:拟使用合计不超30亿元进行投资理财
仁和药业最新公告:2023年净利润5.67亿元 同比下降1.25%
证券之星 · 04-25 16:50
仁和药业最新公告:2023年净利润5.67亿元 同比下降1.25%
仁和药业:截止2024年4月19日,大约10万户左右
证券之星 · 04-23
仁和药业:截止2024年4月19日,大约10万户左右
仁和药业(000650.SZ)子公司获玻璃酸纳滴眼液药品注册证书
智通财经网 · 03-04
仁和药业(000650.SZ)子公司获玻璃酸纳滴眼液药品注册证书
医药界的“南极人”?吾股排名前300,仁和药业:百亿市值,可变现资产高达40亿,董事长增持1个亿
市场资讯 · 2023-11-06
医药界的“南极人”?吾股排名前300,仁和药业:百亿市值,可变现资产高达40亿,董事长增持1个亿
加载更多
公司概况
公司名称:
仁和药业股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-10
主营业务:
仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品等。公司是全国通过GMP认证生产线最多的企业之一。
发行价格:
6.26
{"stockData":{"symbol":"000650","market":"SZ","secType":"STK","nameCN":"仁和药业","latestPrice":6.55,"timestamp":1714115007000,"preClose":6.79,"halted":0,"volume":63528868,"delay":0,"floatShares":1331000000,"shares":1400000000,"eps":0.4001,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.24,"latestTime":"04-26 15:00:00","open":6.6,"high":6.65,"low":6.36,"amount":414000000,"amplitude":0.0427,"askPrice":6.55,"askSize":177,"bidPrice":6.54,"bidSize":1640,"shortable":0,"etf":0,"ttmEps":0.4001,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714354200000},"adr":0,"adjPreClose":6.79,"symbolType":"stock","openAndCloseTimeList":[[1714095000000,1714102200000],[1714107600000,1714114800000]],"highLimit":7.47,"lowLimit":6.11,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1399938234,"pbRate":1.58,"roa":"--","roe":"9.63%","epsLYR":0.41,"committee":0.7446,"marketValue":9170000000,"floatMarketCap":8721000000,"peRate":16.370908,"changeRate":-0.0353,"turnoverRate":0.0477,"status":1},"requestUrl":"/m/hq/s/000650","defaultTab":"news","newsList":[{"id":"2430798294","title":"仁和药业(000650.SZ)发布2023年度业绩,净利润5.67亿元,下降1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430798294","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430798294?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:28","pubTimestamp":1714037323,"startTime":"0","endTime":"0","summary":"仁和药业(000650.SZ)发布2023年年度报告,报告期内,公司实现营业收入5...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/10.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109948.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430475473","title":"仁和药业最新公告:拟使用合计不超30亿元进行投资理财","url":"https://stock-news.laohu8.com/highlight/detail?id=2430475473","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430475473?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:51","pubTimestamp":1714035066,"startTime":"0","endTime":"0","summary":"仁和药业公告,公司拟使用合计不超过人民币30亿元额度的自有经营性盈余资金进行投资理财,上述额度内的投资理财在公司董事会、股东会审议通过之日起12个月内有效并授权公司管理层负责具体实施相关事宜。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033741.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430473428","title":"仁和药业最新公告:2023年净利润5.67亿元 同比下降1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430473428","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430473428?lang=zh_cn&edition=full","pubTime":"2024-04-25 16:50","pubTimestamp":1714035047,"startTime":"0","endTime":"0","summary":"仁和药业发布年报,2023年实现营业收入50.32亿元,同比下降2.35%;净利润5.67亿元,同比下降1.25%。公司拟每10股派发红利2元(含税)。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500033737.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429819645","title":"仁和药业:截止2024年4月19日,大约10万户左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2429819645","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429819645?lang=zh_cn&edition=full","pubTime":"2024-04-23 20:01","pubTimestamp":1713873683,"startTime":"0","endTime":"0","summary":"证券之星消息,仁和药业(000650)04月23日在投资者关系平台上答复投资者关心的问题。投资者:现在股东人数有多少户?仁和药业董秘:谢谢您的关注!截止2024年4月19日,大约10万户左右。具体数据,根据相关法规,请您先向公司证券部提交股东身份证明,谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300038698.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2416159942","title":"仁和药业(000650.SZ)子公司获玻璃酸纳滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2416159942","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2416159942?lang=zh_cn&edition=full","pubTime":"2024-03-04 11:44","pubTimestamp":1709523840,"startTime":"0","endTime":"0","summary":"仁和药业(000650.SZ)发布公告,公司子公司江西闪亮制药有限公司近日收到国家药品监督管理局核准签发的关于玻璃酸纳滴眼液《药品注册证书》。据悉,该药品是以玻璃酸钠为主要成分的滴眼液,临床适应症为:用于干眼症,缓解干眼症状。目前,国内已有多家玻璃酸钠滴眼液上市。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-04/doc-inamcrfu8126424.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-04/doc-inamcrfu8126424.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2381178093","title":"医药界的“南极人”?吾股排名前300,仁和药业:百亿市值,可变现资产高达40亿,董事长增持1个亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2381178093","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2381178093?lang=zh_cn&edition=full","pubTime":"2023-11-06 18:19","pubTimestamp":1699265940,"startTime":"0","endTime":"0","summary":" 2023年7月19日,仁和药业董事长杨潇抛出半年内拟增持1个亿的计划。 对于市值近100亿的公司,占当时股本1.2%。 (月K线;截至2023年10月30日。 2023年11月1日,董事长杨潇已完成1个亿的增持,占总股本1.045,增持后持股6.52%。 前三季度仁和药业的利润也是同比增长:营业收入为38.19亿,同比下降0.7%,扣非净利润为4.67亿,同比增长10.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2023-11-06/doc-imztspfs7459771.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2023-11-06/doc-imztspfs7459771.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1996-12-10","address":"江西省宜春市樟树市葛玄路6号","stockEarnings":[{"period":"1week","weight":0.0366},{"period":"1month","weight":0.0366},{"period":"3month","weight":0.0952},{"period":"6month","weight":0.0089},{"period":"1year","weight":0.1264},{"period":"ytd","weight":0.0241}],"companyName":"仁和药业股份有限公司","boardCode":"AI0027","perCapita":"13313股","boardName":"医药制造业","registeredCapital":"139993万元","compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":0.0071},{"period":"3month","weight":0.049},{"period":"6month","weight":0.0116},{"period":"1year","weight":-0.0647},{"period":"ytd","weight":0.0262}],"survey":" 仁和药业股份有限公司主营业务是生产、销售中西药、原料药及健康相关产品。公司主营产品为口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用洗剂、搽剂、栓剂、软膏剂等剂型药品等。公司是全国通过GMP认证生产线最多的企业之一。","serverTime":1714138959088,"listedPrice":6.26,"stockholders":"100000人(较上一季度减少2.47%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仁和药业,000650,仁和药业股票,仁和药业股票老虎,仁和药业股票老虎国际,仁和药业行情,仁和药业股票行情,仁和药业股价,仁和药业股市,仁和药业股票价格,仁和药业股票交易,仁和药业股票购买,仁和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仁和药业(000650)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仁和药业(000650)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}